25th January 2023

Pharmanovia makes leadership hires in China


  • General Manager and Deputy General Manager appointed to lead growth in China
  • Follows the acquisition of Rocaltrol® (calcitriol) in China from Roche earlier this year

Pharmanovia, The Life Cycle Management Company, today confirmed that it has made two key appointments in China. Ian McAleer joins as General Manager and Sean Xin as Deputy General Manager to lead Pharmanovia’s China operations, based in Shanghai, China.

Ian, who has acquired over sixteen years’ managerial experience across many different roles within the pharmaceutical industry, is adept in business development and operational affairs. Before joining Pharmanovia, Ian was Director of Commercial Operations at Besins Healthcare, introducing and strengthening the position of its commercial infrastructure in the Chinese and Taiwanese pharmaceutical markets. 

Sean, also a specialist in this field, has gained over twenty years of industry expertise, with wide ranging commercial experience in pharmaceuticals and a rich background in product lifecycle management. Having worked in leadership roles for major pharmaceutical companies, including the Novartis group and Sandoz, where he built his expertise in Oncology, leading global commercial operations in this area. 

Pharmanovia CEO, Dr. James Burt commented: “I am pleased to welcome both Ian and Sean to Pharmanovia, who will be instrumental additions to the Chinese Commercial team, as we continue to grow our footprint in the Asia Pacific.

“Earlier this year we acquired Rocaltrol® (calcitriol), expanding our footprint in China. With our two new leadership hires we can further deepen our commitment to China and the team is already looking at ways that we can ensure value added medicines continue to meet the needs of healthcare professionals and their patients.”

Ian McAleer, General Manager added: “Pharmanovia is breaking the boundaries of continuous innovation, building a strong reputation for itself as the leading life cycle management company within the pharmaceutical industry. I am thrilled to be joining a team who is both patient-focused but also passionate about innovation and revitalisation of existing medicines. I look forward to working with the commercial team as we unlock new opportunities with the Asia Pacific region.”

Sean Xin, Deputy General Manager stated: “I am very excited to take on this role at Pharmanovia. I believe that my insights and understanding of China’s pharmaceutical industry will help us to identify new ways our portfolio of value-added medicines can help the Chinese market.”

About Pharmanovia 

Pharmanovia is a global lifecycle management healthcare company. Our mission is to revitalise established medicines for the benefit of patients, prescribers, and payors, and utilise our capabilities to launch novel therapies. With a diverse and growing team in over 140 countries across the globe, we deliver high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Oncology, Endocrinology, Neurology and Cardiovascular.

For further information, please contact:

Alison Dyson, Director of Communications, Pharmanovia

07442 256310/ Alison.dyson@pharmanovia.com 

Or alternatively The PHA Group